| 1.39 0.25 (21.93%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.13 |
1-year : | 2.49 |
| Resists | First : | 1.83 |
Second : | 2.13 |
| Pivot price | 1.18 |
|||
| Supports | First : | 1.27 |
Second : | 0.93 |
| MAs | MA(5) : | 1.16 |
MA(20) : | 1.19 |
| MA(100) : | 1.64  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.7 |
D(3) : | 23.8 |
| RSI | RSI(14): 57.1 |
|||
| 52-week | High : | 6.19 | Low : | 0.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CTOR ] has closed below upper band by 15.9%. Bollinger Bands are 15.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.44 - 1.45 | 1.45 - 1.45 |
| Low: | 1.15 - 1.15 | 1.15 - 1.16 |
| Close: | 1.38 - 1.39 | 1.39 - 1.4 |
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Thu, 04 Dec 2025
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - PR Newswire
Tue, 02 Dec 2025
CTOR - Citius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
Mon, 01 Dec 2025
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - PR Newswire
Thu, 06 Nov 2025
When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable? - Yahoo Finance
Fri, 17 Oct 2025
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 85 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 87.3 (%) |
| Held by Institutions | 10.2 (%) |
| Shares Short | 222 (K) |
| Shares Short P.Month | 251 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.5 % |
| Return on Equity (ttm) | -107.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -3.57 |
| PEG Ratio | 0 |
| Price to Book value | 3.08 |
| Price to Sales | 0 |
| Price to Cash Flow | 932.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|